- Home
- Publications
- Publication Search
- Publication Details
Title
Unleashing the power of NK cells in anticancer immunotherapy
Authors
Keywords
-
Journal
JOURNAL OF MOLECULAR MEDICINE-JMM
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-08-10
DOI
10.1007/s00109-021-02120-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The SIRPα–CD47 immune checkpoint in NK cells
- (2021) Tobias Deuse et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Bone marrow infiltrated natural killer cells predicted the anti-leukemia activity of MCL1 or BCL2 inhibitors in acute myeloid leukemia
- (2021) Yu-Jun Dai et al. Molecular Cancer
- Targeting CD155 by rediocide-A overcomes tumour immuno-resistance to natural killer cells
- (2021) Wanyi Ng et al. PHARMACEUTICAL BIOLOGY
- Expanded human NK cells from lung cancer patients sensitize patients’ PDL1−negative tumors to PD1-blockade therapy
- (2021) Sophie M Poznanski et al. Journal for ImmunoTherapy of Cancer
- It's time to die: BH3 mimetics in solid tumors
- (2021) Sarah Kehr et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
- (2021) Nawid Albinger et al. GENE THERAPY
- Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy
- (2021) Philipp Wendel et al. Cancers
- Ipilimumab and Its Derived EGFR Aptamer-Based Conjugate Induce Efficient NK Cell Activation against Cancer Cells
- (2020) Margherita Passariello et al. Cancers
- Pembrolizumab plus allogeneic NK cells in advanced non–small cell lung cancer patients
- (2020) Mao Lin et al. JOURNAL OF CLINICAL INVESTIGATION
- Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways
- (2020) Teru Hideshima et al. LEUKEMIA
- Arming Cytotoxic Lymphocytes for Cancer Immunotherapy by Means of the NKG2D/NKG2D-Ligand System
- (2020) Mariya Lazarova et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Epigenetic Therapies for Cancer
- (2020) Susan E. Bates NEW ENGLAND JOURNAL OF MEDICINE
- Exploring the NK cell platform for cancer immunotherapy
- (2020) Jacob A. Myers et al. Nature Reviews Clinical Oncology
- Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity
- (2020) Helen Kotanides et al. Cancer Immunology Research
- A novel human anti-TIGIT monoclonal antibody with excellent function in eliciting NK cell-mediated antitumor immunity
- (2020) Dong Han et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Nutlin-3a Enhances Natural Killer Cell–Mediated Killing of Neuroblastoma by Restoring p53-Dependent Expression of Ligands for NKG2D and DNAM-1 Receptors
- (2020) Irene Veneziani et al. Cancer Immunology Research
- NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia
- (2019) Ming-Chin Chang et al. Frontiers in Immunology
- Sorafenib Induces Pyroptosis in Macrophages and Triggers Natural Killer Cell–Mediated Cytotoxicity Against Hepatocellular Carcinoma
- (2019) Carina Hage et al. HEPATOLOGY
- MSC.sTRAIL Has Better Efficacy than MSC.FL-TRAIL and in Combination with AKTi Blocks Pro-Metastatic Cytokine Production in Prostate Cancer Cells
- (2019) Andrea Mohr et al. Cancers
- Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
- (2019) Laurent Gauthier et al. CELL
- NK cells switch from granzyme B to death receptor–mediated cytotoxicity during serial killing
- (2019) Isabel Prager et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Anti–CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control
- (2019) Emilio Sanseviero et al. Cancer Immunology Research
- PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
- (2019) Silvia Pesce et al. Frontiers in Immunology
- Expansion of Human NK Cells Using K562 Cells Expressing OX40 Ligand and Short Exposure to IL-21
- (2019) SoonHo Kweon et al. Frontiers in Immunology
- Molecular Mode of Action of TRAIL Receptor Agonists—Common Principles and Their Translational Exploitation
- (2019) Wajant Cancers
- The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy
- (2019) Yao Liu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- The emerging role of epigenetic therapeutics in immuno-oncology
- (2019) Michael J. Topper et al. Nature Reviews Clinical Oncology
- Systemic and Intra-Nodal Activation of NK Cells After Rituximab Monotherapy for Follicular Lymphoma
- (2019) Monika Enqvist et al. Frontiers in Immunology
- Immunomodulatory Activity of Tyrosine Kinase Inhibitors to Elicit Cytotoxicity Against Cancer and Viral Infection
- (2019) Núria Climent et al. Frontiers in Pharmacology
- The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their ex vivo Expansion and Cytotoxic Potential Against Neuroblastoma: Perspective for Optimized Immunotherapy Post Haploidentical Stem Cell Transplantation
- (2019) Annekathrin Heinze et al. Frontiers in Immunology
- A novel SMAC mimetic APG-1387 exhibits dual antitumor effect on HBV-positive hepatocellular carcinoma with high expression of cIAP2 by inducing apoptosis and enhancing innate anti-tumor immunity
- (2018) Wentao Pan et al. BIOCHEMICAL PHARMACOLOGY
- Sorafenib paradoxically activates the RAS/RAF/ERK pathway in polyclonal human NK cells during expansion and thereby enhances effector functions in a dose- and time-dependent manner
- (2018) J. Lohmeyer et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2018) John F. Seymour et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Murine Natural Cytotoxic Receptor NKp46/NCR1 Controls TRAIL Protein Expression in NK Cells and ILC1s
- (2018) Sam Sheppard et al. Cell Reports
- Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities
- (2018) Aude Le Roy et al. Frontiers in Immunology
- PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy
- (2018) Fatemeh K. Dermani et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
- (2018) Joy Hsu et al. JOURNAL OF CLINICAL INVESTIGATION
- Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies
- (2018) Karl R. VanDerMeid et al. Cancer Immunology Research
- Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells
- (2018) Estefanía Paula Juliá et al. Frontiers in Immunology
- NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination
- (2018) Marcus Ruscetti et al. SCIENCE
- The SMAC Mimetic APG-1387 Sensitizes Immune-Mediated Cell Apoptosis in Hepatocellular Carcinoma
- (2018) Zide Chen et al. Frontiers in Pharmacology
- NKG2D gene polymorphisms are associated with disease control of chronic myeloid leukemia by dasatinib
- (2017) Ryujiro Hara et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation
- (2017) Markus Granzin et al. Frontiers in Immunology
- The Smac Mimetic BV6 Improves NK Cell-Mediated Killing of Rhabdomyosarcoma Cells by Simultaneously Targeting Tumor and Effector Cells
- (2017) Kyra Fischer et al. Frontiers in Immunology
- Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation
- (2016) Brian C. Shaffer et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts
- (2016) S. Vasu et al. BLOOD
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- The DNA methylation profile of activated human natural killer cells
- (2016) John. K. Wiencke et al. Epigenetics
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
- (2016) Rizwan Romee et al. Science Translational Medicine
- Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma
- (2016) T. Kamiya et al. Cancer Immunology Research
- Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study
- (2015) Noriyoshi Iriyama et al. AMERICAN JOURNAL OF HEMATOLOGY
- Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds
- (2015) K. Lagrue et al. BLOOD
- Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
- (2015) Jan Krönke et al. NATURE
- The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma
- (2015) Cinzia Fionda et al. Oncotarget
- Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity
- (2014) Jonathan D. Graves et al. CANCER CELL
- Acute myeloid leukemia impairs natural killer cells through the formation of a deficient cytotoxic immunological synapse
- (2014) Zena Khaznadar et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells
- (2014) J. Du et al. Cancer Immunology Research
- Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN
- (2013) Anita K. Gandhi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib
- (2013) Izuru Mizoguchi et al. CANCER SCIENCE
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Membrane-bound TRAIL Supplements Natural Killer Cell Cytotoxicity Against Neuroblastoma Cells
- (2013) Michael A. Sheard et al. JOURNAL OF IMMUNOTHERAPY
- Second mitochondria-derived activator of caspase (SMAC) mimetic potentiates tumor susceptibility toward natural killer cell-mediated killing
- (2013) Kerstin Brinkmann et al. LEUKEMIA & LYMPHOMA
- Mutational landscape and significance across 12 major cancer types
- (2013) Cyriac Kandoth et al. NATURE
- Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
- (2013) Peter E. Czabotar et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
- (2013) J. Kronke et al. SCIENCE
- New prospects on the NKG2D/NKG2DL system for oncology
- (2013) Evelyn Ullrich et al. OncoImmunology
- The Interaction of NK Cells and Dendritic Cells in the Tumor Environment: How to Enforce NK Cell & DC Action Under Immunosuppressive Conditions?
- (2012) B. Jacobs et al. CURRENT MEDICINAL CHEMISTRY
- Natural killer cells can exert a graft-vs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors
- (2012) Antonio Pérez-Martínez et al. EXPERIMENTAL HEMATOLOGY
- Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells inin vitrostudy
- (2012) Takayoshi Uchiyama et al. HEMATOLOGICAL ONCOLOGY
- Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib
- (2012) Nicole Hassold et al. INTERNATIONAL JOURNAL OF CANCER
- Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
- (2012) Cecele J. Denman et al. PLoS One
- Human NK Cells Are Alerted to Induction of p53 in Cancer Cells by Upregulation of the NKG2D Ligands ULBP1 and ULBP2
- (2011) S. Textor et al. CANCER RESEARCH
- Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression
- (2011) M. R. Parkhurst et al. CLINICAL CANCER RESEARCH
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture Process
- (2011) Jan Spanholtz et al. PLoS One
- Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma
- (2010) G. Gorgun et al. BLOOD
- Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation
- (2010) Benjamin J. Schmiedel et al. INTERNATIONAL JOURNAL OF CANCER
- NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia
- (2010) Jeffrey E. Rubnitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Natural Immunity Enhances the Activity of a DR5 Agonistic Antibody and Carboplatin in the Treatment of Ovarian Cancer
- (2010) Ahmed El-Gazzar et al. MOLECULAR CANCER THERAPEUTICS
- The landscape of somatic copy-number alteration across human cancers
- (2010) Rameen Beroukhim et al. NATURE
- Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells
- (2009) M Lioznov et al. BONE MARROW TRANSPLANTATION
- Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy
- (2009) H. Fujisaki et al. CANCER RESEARCH
- Demethylating treatment suppresses natural killer cell cytolytic activity
- (2009) Xiao-ning Gao et al. MOLECULAR IMMUNOLOGY
- NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma
- (2007) Esther Moga et al. EXPERIMENTAL HEMATOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started